Potentiated BP lowering effect of nitrates or nitric oxide donors (eg, amyl nitrite), including recreational drugs called 'poppers'. Additive BP lowering effect w/ PDE5 inhibitors (eg, sildenafil, tadalafil, vardenafil). Increased mean AUC & mean C
max w/ strong multi pathway CYP & P-gp/BCRP inhibitors [eg, highly active antiretroviral therapy (including different combinations of abacavir, atazanavir, cobicistat, darunavir, dolutegravir, efavirenz, elvitegravir, emtricitabine, lamivudine, rilpivirine, ritonavir, & tenofovir), ketoconazole, posaconazole, itraconazole]; strong P-gp/BCRP inhibitors (eg, cyclosporine A). Potential increase in exposure of riociguat metabolite M1 w/ UGT 1A1 & 1A9 inhibitors. Increased exposure w/ strong CYP1A1 inhibitors (eg, erlotinib, gefitinib), especially in smokers. Potential lowered oral bioavailability w/ drugs that increase upper GI pH. Decreased mean AUC & mean C
max w/ antacid Al/Mg hydroxide. Decreased plasma conc w/ moderate CYP3A4 inducers (eg, bosentan), strong CYP3A4 inducers (eg, phenytoin, carbamazepine, phenobarbitone, St. John's Wort). Reduced exposure w/ smoking. Potential interaction w/ CYP1A1 substrates.